Caris Life Sciences (CAI) Profit After Tax (2024 - 2026)

Caris Life Sciences' Profit After Tax history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• On a quarterly basis, Profit After Tax rose 99.5% year-over-year to -$510000.0 in Q1 2026; TTM through Mar 2026 was -$411.4 million, a 50.46% decrease from a year earlier, with the FY2025 full-year figure at -$68.1 million, up 75.85% from the prior year.
• Profit After Tax slipped to -$510000.0 in Q1 2026 per CAI's latest filing, from $82.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $82.0 million in Q4 2025 and bottomed at -$517.2 million in Q2 2025.
• The 3-year median for Profit After Tax is -$51.5 million (2024), against an average of -$85.6 million.
• Biggest YoY gain for Profit After Tax was 321.78% in 2025; the steepest drop was 682.52% in 2025.
• Year by year, Profit After Tax stood at -$37.0 million in 2024, then surged by 321.78% to $82.0 million in 2025, then tumbled by 100.62% to -$510000.0 in 2026.
• Per Business Quant, the three latest CAI Profit After Tax figures stand at -$510000.0 (Q1 2026), $82.0 million (Q4 2025), and $24.3 million (Q3 2025).